Low rates of major PICC-associated complications attributed in-part to the novel BioFlo catheter material
Data to be presented at
McDiarmid, along with her colleagues
Many of the complication rates seen in this study were lower than previously reported in the literature and can translate to improved patient outcomes. The lower rates were attributed to an experienced nurse-led team, high insertion volumes, standardized protocols for care and maintenance, novel catheter material (BioFlo) and continuous quality improvement initiatives that are implemented and evaluated regularly. The study is available online now and can be found at http://cmajopen.ca/content/5/3/E535.full.
This study was partially funded by a grant provided by
In addition to McDiarmid’s presentation on research from
About BioFlo with Endexo Technology
BioFlo is the only catheter on the market with Endexo Technology, a material more resistant to thrombus accumulation, in-vitro (based on platelet count).1 Endexo Technology is a permanent and non-eluting polymer that is “blended” into the polyurethane from which the catheter is made. It is present throughout the catheter, including extraluminal, intraluminal and cut catheter surface of the tip. Endexo Technology remains present for the life of the catheter. BioFlo catheters are available across AngioDynamics’ Vascular Access family of products, including PICCs, midlines, implantable ports and dialysis catheters.
AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.
AngioDynamics, the AngioDynamics logo and BioFlo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary. Endexo is a trademark and/or registered trademark of Interface Biologics, Inc.
1 The reduction in thrombus accumulation (based on platelet count) is supported by acute in-vitro testing. Pre-clinical in-vitro evaluations do not necessarily predict clinical performance with respect to thrombus formation.